Side-by-side · Research reference
N-Acetyl Epitalon AmidatevsP21
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED12/45 cited
BAnimal-MechanisticHUMAN-REVIEWED8/36 cited
N-Acetyl Epitalon Amidate
Bioregulator Tetrapeptide · Khavinson School
SQ · Variable protocols
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
N-Acetyl Epitalon Amidate
P21
Primary target
DNA promoter regions (telomerase, RNA polymerase II, retinal genes)
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pathway
Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003Khavinson 2004
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Antibody development
—
—
02Dosage Protocols
Parameter
N-Acetyl Epitalon Amidate
P21
Standard dose
No standardized human dosing in indexed literature
In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.
—
Frequency
Not specified in candidate papers
—
Evidence basis
In vitro human cell cultureKhavinson 2004Khavinson 2003
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Cell culture protocol
Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004
Cells made 10 extra divisions (44 passages total vs 34 in control).
—
Duration
Chronic treatment in aging culture
Sustained effect through late passages.
Not specified
Modification stability
N-acetyl + C-amide caps enhance peptidase resistance
Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.
—
Human dosing
—
No established protocol
No clinical trial data available.
Animal models (mice)
—
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
Route
—
Presumed subcutaneous or intraperitoneal (animal studies)
04Side Effects & Safety
Parameter
N-Acetyl Epitalon Amidate
P21
Human safety data
Not available in indexed literature
Candidate papers describe in vitro and animal models only.
None available
No clinical trials in humans.
Theoretical telomerase risk
Telomerase activation in somatic cells raises theoretical oncogenic transformation concern
—
Animal tolerability
—
Well-tolerated in mouse models; no toxicity reported in available abstracts
Theoretical risks
—
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
Absolute Contraindications
N-Acetyl Epitalon Amidate
- ·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization
P21
- ·Use in humans not validated
Relative Contraindications
N-Acetyl Epitalon Amidate
- ·Individuals with hereditary cancer syndromes or high genetic cancer risk
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
05Administration Protocol
Parameter
N-Acetyl Epitalon Amidate
P21
1. Route
Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.
Not established. No FDA approval, no clinical trial data.
2. Reconstitution
Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
3. Storage
Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.
—
4. Clinical protocols
Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.
—
06Stack Synergy
N-Acetyl Epitalon Amidate
+ Thymalin
ModerateBoth are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.
- Epitalon
- Protocol not defined in indexed literature
- Thymalin
- Tissue-specific bioregulator · separate dosing
- Rationale
- Complementary transcriptional targets
- Primary benefit
- Dual-axis aging intervention: cellular senescence + immune restoration
P21
— no documented stacks